PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-10-17 (1)

Date Title Company
17-Oct-2023 FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery Businesswire